C12N 2310/50
Physical structure
C12N2310/50 (Physical structure) appears on 2,405 US grants and 4,872 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,405
- Published applications
- 4,872
- Assignees
- 1,528
- Inventors
- 7,521
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 6 | 0 |
| 1996 | 8 | 0 |
| 1997 | 27 | 0 |
| 1998 | 43 | 0 |
| 1999 | 17 | 0 |
| 2000 | 16 | 0 |
| 2001 | 18 | 1 |
| 2002 | 14 | 19 |
| 2003 | 9 | 67 |
| 2004 | 5 | 109 |
| 2005 | 9 | 163 |
| 2006 | 15 | 114 |
| 2007 | 14 | 96 |
| 2008 | 24 | 98 |
| 2009 | 39 | 155 |
| 2010 | 68 | 149 |
| 2011 | 65 | 170 |
| 2012 | 92 | 121 |
| 2013 | 98 | 131 |
| 2014 | 118 | 173 |
| 2015 | 122 | 246 |
| 2016 | 112 | 255 |
| 2017 | 153 | 242 |
| 2018 | 158 | 253 |
| 2019 | 175 | 260 |
| 2020 | 165 | 266 |
| 2021 | 135 | 261 |
| 2022 | 146 | 304 |
| 2023 | 142 | 329 |
| 2024 | 132 | 320 |
| 2025 | 127 | 333 |
| 2026 | 132 | 237 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement6 Oct 2026US 12,753,411 B2The Brigham and Women S Hospital, Inc.
- Methods of activating cells via PTP 1B inhibition29 Sep 2026US 12,746,285 B2Monash University
- Compositions and methods for reprogramming age-restricted non-neuronal cells29 Sep 2026US 12,747,438 B2The Regents of the University of California
- Use of FcgammaRIII inhibitor in preparation of medicament for treating pulmonary fibrosis15 Sep 2026US 12,735,489 B2Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
- Enzymes with RUVC domains15 Sep 2026US 12,735,688 B2Metagenomi Therapeutics, Inc.
- Methods and compositions for microbial delivery of double stranded rna8 Oct 2026US 2026/0305618 A1Rnaissance AG LLC
- Sugar Modified Oligonucleotides and Uses Thereof8 Oct 2026US 2026/0308587 A1Ionis Pharmaceuticals, Inc.
- Nucleic acids encoding crispr-associated proteins and uses thereof8 Oct 2026US 2026/0308602 A1CureVac AG
- Compositions and methods for recombinant aav production8 Oct 2026US 2026/0308620 A1REGENXBIO Inc.
- Methods for treating gastrointestinal inflammatory diseases using alpha-ketoglutarate (akg) modulators1 Oct 2026US 2026/0294856 A1
Most cited
By later US patents
- Genetic inhibition by double-stranded RNA1,185US 6,506,559 B1Carnegie Institute of Washington · 2003
- Methods for identifying nucleic acid ligands856US 5,270,163 AUniversity Research Corporation · 1993
- Nucleic acid ligands561US 5,475,096 AUniversity Research Corporation · 1995
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014